Redeye provides an update on Scandinavian ChemoTech following the Q4 2025 report. Sales were softer than expected, while solid cost control continued. We underestimated the seasonal effects in the fourth quarter and do not place too much weight on the reported revenue figure. We make only minor adjustments to our estimates and reiterate our fair value range of SEK2-10, with a base case of SEK6.3.
LÄS MER
